What Was Theranos and How Did Elizabeth Holmes’s Blood-Testing Scandal Work?
Theranos was a health technology company that promised to change medicine with a few drops of blood. Its founder, Elizabeth Holmes, started the company while she was still a teenager. She said its technology could run medical tests using only a few drops of blood. That claim drew famous investors, produced a $9 billion valuation, and made Holmes the youngest self-made female billionaire in the United States. It was also false.
A Teenager's Promise, a Billion-Dollar Valuation
Holmes founded Theranos as a teenager, according to reporting in The Guardian. The pitch was radical: a technology that could perform medical tests from a tiny amount of blood. By 2014, Theranos was valued at $9 billion. Holmes was named the youngest female self-made billionaire in the US, with a net worth of $4.5 billion by the time she was 30.
The investor and board list helped sustain the story. It included Rupert Murdoch, Larry Ellison, Carlos Slim, and former secretaries of state Henry Kissinger and George Shultz. The Guardian reports that Holmes mesmerised them. But the company's central technology did not work as advertised. The Guardian describes Theranos as an illusion and a confidence trick built on a scam.
From a $9 Billion Company to a Prison Sentence
Holmes quit as chief executive in 2018, and Theranos collapsed that same year. In 2022, she was sentenced to more than 11 years in prison for wire fraud and conspiracy. She was due to report to federal prison camp Bryan in Texas. The sentence marked the end of the criminal case, not the end of the story.
Why the Fraud Still Casts a Shadow
Theranos remains a reference point because it was not just one company's failure. The Guardian argues that the founder culture and obsession of Silicon Valley that helped Holmes become who she was is still alive and well, and stronger than ever. The same reporting notes that power and wealth have rarely been concentrated in so few hands.
That tension has not faded with the prison sentence. The Guardian reported that Holmes and Evans were planning a new medical tech startup as she prepared to enter prison. In 2025, two years into her sentence, Evans sought $18.5 million for Haemanthus, a company allegedly holding patents for a device claiming to scan blood, urine, and saliva samples using lasers. The status of that company and the claims about its technology cannot be confirmed from the available record.
What the Theranos case leaves behind is a durable warning about how persuasive founders, eager investors, and weak early scrutiny can combine. It also explains why the name Elizabeth Holmes still prompts a simple question: how did so many people believe a blood-testing claim that could not be verified?